Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors

NCT05671510 is registered in ClinicalTrials.gov with OncoC4, Inc. as lead sponsor.

NCT NCT05671510
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05671510 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors
Lead sponsor
OncoC4, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 28, 2023
Completion date
August 31, 2028
Enrollment
630 (estimated)
Sites
152

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer